首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1391篇
  免费   87篇
  国内免费   9篇
耳鼻咽喉   15篇
儿科学   42篇
妇产科学   22篇
基础医学   145篇
口腔科学   72篇
临床医学   192篇
内科学   241篇
皮肤病学   19篇
神经病学   64篇
特种医学   165篇
外科学   137篇
综合类   31篇
预防医学   199篇
眼科学   10篇
药学   90篇
中国医学   1篇
肿瘤学   42篇
  2021年   9篇
  2019年   14篇
  2018年   13篇
  2017年   11篇
  2016年   9篇
  2015年   17篇
  2014年   29篇
  2013年   36篇
  2012年   26篇
  2011年   35篇
  2010年   38篇
  2009年   47篇
  2008年   41篇
  2007年   37篇
  2006年   41篇
  2005年   49篇
  2004年   41篇
  2003年   51篇
  2002年   34篇
  2001年   32篇
  2000年   30篇
  1999年   31篇
  1998年   31篇
  1997年   44篇
  1996年   52篇
  1995年   35篇
  1994年   29篇
  1993年   41篇
  1992年   16篇
  1991年   27篇
  1990年   26篇
  1989年   26篇
  1988年   25篇
  1987年   37篇
  1986年   33篇
  1985年   23篇
  1984年   12篇
  1983年   14篇
  1982年   21篇
  1981年   12篇
  1980年   12篇
  1978年   10篇
  1977年   13篇
  1976年   14篇
  1975年   8篇
  1974年   8篇
  1929年   17篇
  1928年   8篇
  1924年   8篇
  1922年   9篇
排序方式: 共有1487条查询结果,搜索用时 343 毫秒
1.
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment.  相似文献   
2.
3.
目的:观察开道散合扶正和胃合剂治疗上消化道癌性狭窄的临床疗效。方法:对40例患者采用口服开道散、扶正和胃合剂联合胃镜下癌灶内注射5-氟脲嘧啶注射液及鸦胆子乳剂方法治疗上消化道癌性狭窄。结果:治疗后无瘤灶消失病例,34例患者肿瘤缩小达50%以上,完全缓解0例,部分缓解34例,稳定4例,进展2例,有效率为85.0%。治疗后患者吞咽困难有了较明显的改善,显效7例,有效31例,无效2例,总有效率95.0%。治疗后所有患者的卡氏评分均有所升高,与治疗前比较,差异有显著性意义(P〈0.05),提示治疗后患者的生活质量有所改善。结论:开道散合扶正和胃合剂治疗上消化道癌性狭窄疗效满意,能使实体瘤缩小、吞咽困难改善、生活质量提高。  相似文献   
4.
5.
Org 20781, the major metabolite of Org 7797 found in in-vitro experiments was examined for antiarrhythmic and electrophysiological effects in-vivo. Org 20781 (0·5–2·0 mg kg?1 i.v.) inhibited the development of early ischaemia-induced arrhythmias in rats, suppressed spontaneous ventricular tachycardia (VT) in conscious dogs with 24-h old infarcts, and prevented electrical induction of VT in dogs with 5–6-day old infarcts, actions associated with slowing of conduction at all levels of the myocardium. Cardiac refractory periods were only modestly prolonged whilst repolarization was unchanged. Peak plasma levels of the parent compound (infused to total doses of 2–4mg kg?1) associated with suppression of late arrhythmias were 6–18 μm, whilst the mean plasma elimination half-life (in normal dogs) was 107 min. It was concluded that the major metabolite has a similar antiarrhythmic and electrophysiological profile to the parent compound, is at least half as potent and may contribute to the therapeutic effects of Org 7797 administration.  相似文献   
6.
7.
Forty conventional radiographs with examples of mild interstitial infiltrates and subtle pneumothoraces and 40 normal studies of the chest were selected and digitized, with pixel sizes of 1.0, 0.5, 0.2, and 0.1 mm. Observer performance tests were carried out using receiver operating characteristic analysis. Conventional radiographs and digitized images were compared. The results indicate that, in such cases, diagnostic accuracy increases significantly as the pixel size is reduced, at least to the 0.1-mm level. We conclude that, for digital systems using screen-film or similar image receptors, use of a pixel size substantially larger than 0.1 mm may result in some loss of diagnostic accuracy.  相似文献   
8.
9.
The antiarrhythmic efficacy of 17 beta-amino- and 17 beta-amino-16 alpha-hydroxyestratrien-3-ols and 3-acetates (group 1) was compared with the efficacy of corresponding 3-[2-hydroxy-3-(isopropylamino)propyl] and 3-[2-hydroxy-3-(tert-butylamino)propyl] ethers (group II), substituents which are usually associated with beta-adrenoceptor blocking activity. Group I compounds exerted potent antiarrhythmic activity against both aconitine-induced arrhythmias in mice and ischemia-induced arrhythmias in rats and reduced the maximum following frequency of isolated guinea pig atria. Electrophysiological studies indicated that their mechanism of action is due to an ability to reduce the fast inward sodium current in cardiac cells (class I antiarrhythmic action). Group II compounds were inactive in the aconitine and atrial tests and electrophysiological studies confirmed that they were devoid of class I activity. However, these compounds, like both class I antiarrhythmic and beta-adrenoceptor blocking drugs, were active against ischemia-induced arrhythmias. Group II compounds, unlike group I compounds, exerted nonspecific beta-adrenoceptor blocking actions, which may account for their activity in the rat test. It was concluded that introduction of the 3-substituted ether group did not confer any advantage over the parent 3-ol or 3-acetate compounds.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号